What the latest evidence shows for knee osteoarthritis

The finding

On 6 January 2026, Wang and colleagues published a systematic review in Frontiers in Cell and Developmental Biology pooling eleven randomized controlled trials of mesenchymal stem cell (MSC) therapy for osteoarthritis, covering 811 patients.

Across those trials, patients who received MSC therapy reported substantially less pain and better joint function than controls, on several independent measurement scales:

The detail the authors themselves highlight is the two-year mark. Effects that come mainly from expectation tend to fade; these did not. Improvement was still measurable at 24 months, and the authors argue that this time-dependent pattern “supports genuine therapeutic activity beyond placebo effects.”¹

Safety, which is usually the first question

Across all eleven trials, the adverse events reported were overwhelmingly transient and local: pain, swelling or effusion at the injection site, typically resolving within a few days. A few studies noted brief fever or headache.

What “not FDA-approved” actually means

This phrase does a lot of work in conversations about regenerative medicine, and it is worth being precise about it, because it is neither a warning label nor a technicality.

It means the U.S. Food and Drug Administration has not licensed this therapy for this indication. It does not mean the therapy has been reviewed and rejected, and it does not mean it is unregulated everywhere. Approval is a jurisdiction-by-jurisdiction process that requires a sponsor to fund and run large, expensive phase III programmes for a specific product and a specific use — a commercial and logistical undertaking as much as a scientific one. Plenty of therapies in routine use in one country are still unlicensed in another.

What it does mean, practically, is that the burden of judgement falls on you and on the physician assessing you, rather than on a regulator who has already decided. That is exactly why the questions further down matter, and why any clinic worth considering should welcome them.

In México, cellular therapy is regulated by COFEPRIS, which licenses the facility and the procedures performed in it. That is a different framework from FDA approval of a product, and it is worth understanding the difference rather than treating either as a substitute for the other.

Where the evidence is still soft

A field is more convincing when it tells you what it does not know, so here is the honest inventory.

• The trials vary a great deal. Heterogeneity was high (I² up to 98%), driven by differences in cell source, dose and control treatment. Pooled averages across such different protocols should be read as a direction, not a prescription.
• Blinding is genuinely hard. If your knee is injected with something visibly different from saline, you may guess which group you are in, and that influences what you report.
• How much is context? A separate 2025 analysis of eight placebo-controlled trials estimated that a substantial share of reported improvement is attributable to contextual effects rather than to the cells themselves.² The January 2026 pooling, which is larger and follows patients longer, points to a real effect persisting at two years. Both findings can be true at once: context contributes, and something beyond context appears to remain.
• Dose and cell source are unsettled. This is where the field's biggest open arguments sit, and it is the main reason results are not directly comparable between clinics.
• Structural change is not established. Symptom improvement is well-documented; imaging evidence that cartilage itself is restored is much thinner.

None of this makes the therapy unpromising. It makes it early — and being early is a reason to ask better questions, not a reason to stop asking them.

If you want to look into this further

The single most useful thing you can do is put your own case in front of someone qualified to assess it, because the averages above describe a pooled population and you are not a pooled population. Stage of disease, prior surgery, medication and general health all change the picture.

Practical next steps, in the order that saves the most time:

• Gather your imaging. MRI, X-ray, CT or ultrasound of the joint from the last twelve months — the images, not only the report.
• Write down what you have already tried. Physical therapy, injections, surgery, and whether any of it helped and for how long.
• List your medications. Blood thinners and anti-inflammatories matter a great deal here.
• Ask your own physician what they think. A second opinion is more useful when the first one is on record.
• Have your records reviewed by a physician who works in this area and ask for the assessment in writing, including the reasoning.

Questions worth asking any clinic

• What does the published evidence say for my condition and stage, and how certain is it?
• What is the realistic magnitude of benefit, and how long does it typically last?
• What cell source and dose do you use, and why that one?
• Who reviews my records before anyone tells me I am a candidate?
• What follow-up exists at three, six and twelve months?
• What happens if it does not work — what is the plan?

A clinic that answers these plainly, including the parts that are uncertain, is telling you something useful about how it will behave later.

See how a records review works at Medgenik →